Nuvalent Inc - Ordinary Shares - Class A Stock

$99.10

1.93% yesterday

Nasdaq, Sep 27, 10:00 pm CET

ISIN

US6707031075

Symbol

NUVL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Nuvalent Inc - Ordinary Shares - Class A Stock price

$99.10

+80.35 428.53% 5Y

Nasdaq, Closing price Fri, Sep 27 2024

-1.95 1.93%

ISIN

US6707031075

Symbol

NUVL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$7.05b
Enterprise Value	$6.40b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	10.27
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-202.96m
Free Cash Flow (TTM) Free Cash Flow	$-130.44m
Cash position	$657.99m
EPS (TTM) EPS	$-2.78
P/E forward	negative
Short interest	31.27%

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Get Started for Free Today

Nuvalent Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

??

12 Analysts have issued a Nuvalent Inc - Ordinary Shares - Class A forecast:

12x Buy

100%

More details on Analyst Estimates Including Price Targets

12 Analysts have issued a Nuvalent Inc - Ordinary Shares - Class A forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Nuvalent Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '24		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	50 50	76% 76% -
- Research and Development Expense	153 153	79% 79% -
EBITDA	-203 -203	78% 78% -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-203 -203	78% 78% -
Net Profit	-174 -174	73% 73% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Nuvalent Inc - Ordinary Shares - Class A Stock News

Positive

Seeking Alpha

●

4 days ago

Nuvalent: Promising Data Keeps Validating Pipeline And Platform

Nuvalent's lead candidates, NVL-520 and NVL-655, show promising efficacy and safety in Phase 1/2 trials. Both drugs have received FDA Breakthrough Therapy and orphan drug designations, with pivotal Phase 2 data expected in 2025 and potential approvals by 2026. The company completed a $500 million secondary offering, reflecting strong investor interest and providing the cash runway through Phase 3.

Neutral

PRNewsWire

●

9 days ago

Nuvalent Announces Closing of Upsized Public Offering of Common Stock

CAMBRIDGE, Mass. , Sept. 18, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the closing of its previously announced upsized underwritten public offering of 5,750,000 shares of Class A common stock, which includes 750,000 shares of Class...

Positive

Seeking Alpha

●

10 days ago

Nuvalent: NSCLC Program Now Lends Credibility Towards 2025 Pivotal Data Releases

Nuvalent, Inc. achieved positive data from the phase 1/2 ALKOVE-1 study, using NVL-655 for the treatment of patients with ALK-mutant NSCLC. Positive data achieved from phase 1/2 ARROS-1 study, using zidesamtinib for the treatment of patients with ROS-1 mutant NSCLC. The global non-small cell lung cancer market size is projected to reach $36.9 billion by 2031; 3% to 5% are ALK-positive and then ...

More Nuvalent Inc - Ordinary Shares - Class A News

Company Profile

Nuvalent, Inc. operates as a preclinical stage biopharmaceutical company. The company creates precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Its focus its discovery efforts on small molecule inhibitors of kinases, a class of cellular targets that can play a central role in cancer growth and proliferation. The company was founded in January 2017 and is headquartered Cambridge, MA.

Head office	United States
CEO	James Porter
Employees	92
Founded	2017
Website	www.nuvalent.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now